Louise Howard

In GPCR drug discovery, as elsewhere, teams know the cost of getting early decisions wrong. A corrected JAMA analysis of 63 new drugs and biologics approved by the US Food and Drug Administration between 2009 and 2018 estimated the median capitalised R&D investment at $1.14 billion per product, after accounting for the costs of failed trials [1]. Although attrition has many causes, some of the most consequential decisions are made much earlier.

It’s 3am. Thoughts are racing in circles, and there is no one to talk to: friends are asleep, the next appointment with a psychotherapist is weeks away, and not everyone can afford one. So a person either lies awake, scrolls endlessly through social media, or turns to an AI mental health app. More and more people find themselves in this situation.

Healthcare is changing faster than I have ever seen it change, and the revenue cycle has to keep pace. We are talking about AI, new treatments, new technology, new specialties and entirely new ways of delivering care. All of that is exciting, and much of it has the potential to improve how we take care of patients.